Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG:2315)
53.50
+0.50 (0.94%)
Feb 13, 2026, 4:08 PM HKT
Biocytogen Pharmaceuticals (Beijing) Employees
Biocytogen Pharmaceuticals (Beijing) had 1,306 employees as of June 30, 2025. The number of employees increased by 189 or 16.92% since the number was reported on December 31, 2024.
Employees
1,306
Change
189
Growth
16.92%
Revenue / Employee
999.22K HKD
Profits / Employee
110.93K HKD
Market Cap
35.09B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 1,306 | 189 | 16.92% |
| Dec 31, 2024 | 1,117 | 51 | 4.78% |
| Dec 31, 2023 | 1,066 | -282 | -20.92% |
| Dec 31, 2022 | 1,348 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| 3SBio | 6,268 |
| Genscript Biotech | 5,769 |
| Shanghai Henlius Biotech | 3,537 |
| RemeGen | 3,070 |
| Shanghai Junshi Biosciences | 2,670 |
| Keymed Biosciences | 1,469 |
| InnoCare Pharma | 1,176 |
| Ascentage Pharma Group International | 605 |
Biocytogen Pharmaceuticals (Beijing) News
- 8 days ago - Strengthening Translational Research in India: GVSAP and Biocytogen Expand Collaboration - Business Upturn
- 5 months ago - Biocytogen Enters into Agreement with Merck, KGaA, Darmstadt, Germany to Advance Antibody-Conjugated Lipid-Based Delivery Solutions - Financial Post
- 7 months ago - Biocytogen Upgrades Preclinical Service Platform and Launches Revamped Global Website - Business Upturn
- 7 months ago - Biocytogen Enters into Antibody Licensing Agreement with BeOne Medicines to Accelerate Innovative Drug Development - Financial Post
- 8 months ago - Biocytogen Responds to Harbour BioMed’s Patent Claims: RenNano® is an Independently Developed Platform with Distinct Innovation and Full Legal Standing - Financial Post
- 9 months ago - Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform - Business Upturn
- 9 months ago - Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009) - Financial Post
- 1 year ago - Biocytogen and Acepodia Join Forces to Advance Bispecific Antibody and Dual-Payload ADCs for Treating Complex Tumors - Financial Post